Dr. Peter Blume-Jensen is Acrivon's main founder and has served as its Chief Executive Officer, acting Chief Scientific Officer and President since March 2018 and as Chairman of the Board since October 2020. He is the inventor of the founding AP3 (Acrivon Predictive Precision Proteomics) platform and the OncoSignature patient-selection method. He previously served as Chief Scientific Officer at XTuit Pharmaceuticals and at Metamark Genetics, as Vice President and Global Therapeutic Area Advisor for Oncology at Daiichi Sankyo, and as a department head at Merck & Co. and Serono, US. His review 'Oncogenic Kinase Signaling' (Nature, 2001) is a citation classic in clinical medicine. Dr. Blume-Jensen received his M.D. from Copenhagen University Medical School, his Ph.D. from the Ludwig Institute for Cancer Research in Uppsala, Sweden, and conducted his post-doctoral fellowship under Tony Hunter at the Salk Institute.